Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Weighted Average) (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Shares Outstanding (Weighted Average) data on record, last reported at $84.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 58440.79% year-over-year to $84.8 million; the TTM value through Dec 2025 reached $84.8 million, up 58440.79%, while the annual FY2025 figure was $84.8 million, 58440.79% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $84.8 million in Q4 2025 per VRDN's latest filing, up from $134864.0 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $84.8 million in Q4 2025 and bottomed at $134864.0 in Q3 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $23.0 million, with a median of $10.2 million recorded in 2021.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 58440.79% in 2025, down 99.77% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $11.9 million in 2021, then plummeted by 98.3% to $203190.0 in 2022, then dropped by 14.25% to $174226.0 in 2023, then fell by 16.85% to $144862.0 in 2024, then surged by 58440.79% to $84.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $84.8 million in Q4 2025, $134864.0 in Q3 2025, and $145160.0 in Q2 2025.